Matthew Link Sells 5,042 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 5,042 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $2.31, for a total transaction of $11,647.02. Following the completion of the transaction, the insider now owns 830,551 shares in the company, valued at approximately $1,918,572.81. The trade was a 0.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $2.30 on Friday. The firm has a market capitalization of $118.07 million, a price-to-earnings ratio of -2.25 and a beta of 2.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The company’s 50-day moving average is $2.67 and its two-hundred day moving average is $3.86. Sight Sciences, Inc. has a 1-year low of $2.04 and a 1-year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period in the previous year, the company posted ($0.22) EPS. Analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SGHT shares. Citigroup cut their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Lake Street Capital lowered their target price on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a report on Thursday, March 6th. Piper Sandler decreased their target price on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus dropped their price target on Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, UBS Group dropped their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Sight Sciences presently has an average rating of “Hold” and an average price target of $3.83.

Institutional Trading of Sight Sciences

A number of institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in Sight Sciences in the fourth quarter valued at $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in Sight Sciences in the fourth quarter valued at about $40,000. Arkadios Wealth Advisors acquired a new stake in shares of Sight Sciences in the 4th quarter valued at approximately $47,000. WealthTrust Asset Management LLC acquired a new stake in Sight Sciences in the fourth quarter valued at $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Sight Sciences during the fourth quarter worth about $50,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.